Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Izzy who wrote (3078)	12/2/1997 8:46:00 PM
From: JOHN W.	Respond to of 6136

No comment on the good news about PIs released today.....certainly got loss in the storm Tuesday December 2 3:19 PM EST Drugs shown to reverse AIDS dementia UPI Science News CHICAGO, Dec. 2 (UPI) _ Researchers are showing that the anti-AIDS drug cocktails that often have dramatically reduced levels of the AIDS virus can halt _ or even reverse _ dementia caused by the viral infection. At the Radiological Society of North America, doctors say today brain scans prove protease inhibitors along with other anti-viral medications change the course of AIDS dementia complex sufficiently to allow some terminally ill, nurse-dependent patients to return to work. Dr. Christopher Filippi of Albert Einstein College of Medicine, New York City, tells United Press International, ''We did not expect to see this improvement in a brain disease that had been considered irreversible.'' In nine endstage AIDS patients who underwent magnetic resonance imaging (MRI), Filippi says the brain scans showed no change in one patient; stabilization in four patients and reversal of the disease in four others. More than half the people infected with AIDS develop the disease known as HIV-encephalopathy _ in which white matter of the brain is attacked, causing loss of motor function and memory. Filippi, assistant professor of radiology and director of neuroradiology at Weiler Hospital, says, ''Until now, HIV-encephalopathy has been considered to be relentlessly progressive. This is the first study that demonstrates clinical neurological improvement with the use of protease inhibitors that correlates with an improvement seen on brain MRI scans.'' Filippi says the patients in the study had less than a year to live and many were nurse-dependent when they began taking the three-drug cocktail containing protease inhibitors. All are still alive 14 months later, some improved enough to get around on their own and in a few cases their short-term memory problems lifted enough for them to return to work. (Written by Ed Susman from West Palm Beach, Fla.) _- Copyright 1997 by United Press International All rights reserved _-

To: Izzy who wrote (3078)	12/2/1997 8:54:00 PM
From: JOHN W.	Respond to of 6136

I bought more today too. I will go down with the ship if it sinks. If you are still confident in AG3340, then you should be very happy with Agouron reacquiring all of the rights to all of their cancer drugs.

To: Izzy who wrote (3078)	12/2/1997 8:56:00 PM
From: billkirn	Read Replies (2) \| Respond to of 6136

Izzy: You have lots of questions, and I have no answers. This could be a great time to dollar cost average your way in over the next few months, to hold for the next 5 years. I think we have reached a good value for the company. Also you could buy some calls, to lock in a good share price, and wait for the dust to settle. If there is more serious selling you can buy at lower prices and if something big happens in the next 6 months you have locked in a reasonable price. Just my plan. As Maggie wants me to say, IMO. Bill Kirn